Krikelis Dimitrios, Skoura Evangelia, Kotoula Vassiliki, Rondogianni Phivi, Pianou Nikoletta, Samartzis Alexandros, Xanthakis Ioannis, Fountzilas George, Datseris Ioannis E
Department of Medical Oncology, Papageorgiou Hospital, Nea Efkarpia Ring Road, PC 564 29, Thessaloniki, Greece.
Anticancer Res. 2014 May;34(5):2571-9.
Although Kirsten rat sarcoma (KRAS) gene mutational testing is essential for the optimal design of therapeutic strategies for colorectal cancer, it is not always feasible or reliable. In this retrospective study, we examined whether (18)F-Fluorodeoxyglucose positron-emission tomography/computed tomography ((18)F-FDG PET/CT) scans can serve as a surrogate examination for KRAS mutational testing.
KRAS codon 12 and 13 mutational status was tested in 44 colorectal primary tumors and was compared with the (18)F-FDG PET/CT maximum standardized uptake value (SUVmax) values of the respective metastatic lesions. Glucose transporter-1 (GLUT1) mRNA levels were also measured in colorectal primary tumors.
No statistically significant correlation between (18)F-FDG PET/CT SUVmax values and KRAS mutation status was found (parametric t-test: p=0.4753; non-parametric Kruskal-Wallis test: p=0.51). This result cannot be attributed to the effect of differing GLUT1 mRNA levels, as shown by multivariate analysis.
Our study failed to promote (18)F-FDG PET/CT uptake as a surrogate examination for KRAS mutation testing.
尽管 Kirsten 大鼠肉瘤（KRAS）基因突变检测对于结直肠癌治疗策略的优化设计至关重要，但它并不总是可行或可靠的。在这项回顾性研究中，我们检查了氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-FDG PET/CT）扫描是否可以作为 KRAS 基因突变检测的替代检查。
对 44 例结直肠癌原发性肿瘤进行 KRAS 密码子 12 和 13 的突变状态检测，并与相应转移病灶的 18F-FDG PET/CT 最大标准化摄取值（SUVmax）进行比较。还测量了结直肠癌原发性肿瘤中葡萄糖转运蛋白-1（GLUT1）的 mRNA 水平。
未发现 18F-FDG PET/CT SUVmax 值与 KRAS 突变状态之间存在统计学显著相关性（参数 t 检验：p = 0.4753；非参数 Kruskal-Wallis 检验：p = 0.51）。多变量分析表明，该结果不能归因于不同 GLUT1 mRNA 水平的影响。
我们的研究未能将 18F-FDG PET/CT 摄取作为 KRAS 突变检测的替代检查。
